Want to join the conversation?
Pharma giant $GILD said that the EU has granted authorization to market the once-daily Truvada combined with safer-sex practices to reduce risk of HIV-1 infection among high-risk uninfected adults, also known as pre-exposure prophylaxis (PrEP). Truvada is currently the most prescribed antiretroviral drug in Europe as part of combination therapy.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.